Previous 10 | Next 10 |
The following slide deck was published by Cytosorbents Corporation in conjunction with this event. For further details see: Cytosorbents (CTSO) 2022 Annual Shareholders Meeting - Slideshow
Penny stocks can have huge potential if you know how to trade them. Lower prices present opportunities to capitalize on small moves. These aren’t 5%, or 10% jumps either. In one trading session, some stocks under $5 can experience explosive moves. But that doesn’t mean these b...
Gainers: Aero Clean Technologies AERC +49%. Houston American Energy (HUSA) +37%. Jan One JAN +37%. Oncorus (ONCR) +41%. Cytosorbents (CTSO) +33%. Mirati Therapeutics MRTX +30%. Omega (OMGA) +27%. Codiak BioSciences (CDAK) +27%. Quantum Computing (QUBT) +26%. GitLab GTLB...
CytoSorbents to Hold 2022 Annual Meeting of Stockholders Virtually PR Newswire PRINCETON, N.J. , June 2, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit ...
CytoSorbents Partners with Nikkiso to Distribute the PureADJUST Hemoperfusion Blood Pump and Supplies in 14 Countries PR Newswire Stand-alone Blood Pump Business Model is expected to Enable Expanded Use and Increased Adoption of CytoSorb ® PR...
CytoSorbents to Present at Two Upcoming Investor Conferences PR Newswire MONMOUTH JUNCTION, N.J. , May 19, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care uni...
Cytosorbents Corporation (CTSO) Q1 2022 Earnings Conference Call May 03, 2022 04:30 PM ET Company Participants Terri Anne Powers - Vice President, Investor Relations & Corporate Communications Phillip Chan - Chief Executive Officer Vincent Capponi - President & Chief Operating Officer...
The following slide deck was published by Cytosorbents Corporation in conjunction with their 2022 Q1 earnings call. For further details see: Cytosorbents Corporation 2022 Q1 - Results - Earnings Call Presentation
Cytosorbents (NASDAQ:CTSO) stock fell May 4, after the company's Q1 results missed analysts' estimates. Total revenue declined -18% Y/Y to $8.69M. Q1 product sales decreased 22% Y/Y to $7.9M. The company said the decrease was mainly due to a reduction in German direct sales, which were hamper...
Cytosorbents press release (NASDAQ:CTSO): Q1 GAAP EPS of -$0.21 misses by $0.06. Revenue of $8.69M (-18.0% Y/Y) misses by $1.32M. For further details see: Cytosorbents GAAP EPS of -$0.21 misses by $0.06, revenue of $8.69M misses by $1.32M
News, Short Squeeze, Breakout and More Instantly...
CytoSorbents Corporation Company Name:
CTSO Stock Symbol:
NASDAQ Market:
CytoSorbents Corporation Website:
PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces that it has regained comp...
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, is proud to announce the launch of ...
PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces it will present...